Quercetin: What the Research Covers (2026)
Educational overview — not medical advice. Quercetin is not a substitute for prescribed blood-pressure medication or antihistamines, and there is no long-term (12-week+) human safety data at high doses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Two areas of research, one buyer-relevant catch. Three meta-analyses (Serban 2016, Huang 2020, Popiolek-Kalisz 2022) pooled trials of plain quercetin and reported small changes in blood pressure readings, with results at 500 mg/day and up. A smaller body of research looked at seasonal allergy symptoms, mostly in phytosome-form trials. This page does not say quercetin treats any condition. The catch: plain quercetin absorbs poorly, and phytosome (Quercefit) forms reached up to 20x higher plasma levels per mg (Riva 2019) — so a milligram of one is not a milligram of the other.
As an Amazon Associate we earn from qualifying purchases. On best quercetin, products are ranked by form (plain vs phytosome, never pooled) and disclosed mg first, not commissions.
Start here
What quercetin is, and the two areas studied
Quercetin is a flavonoid found in onions, apples, berries, and other plants, sold as a supplement in two structurally different forms: plain (unformulated) quercetin dihydrate, and phytosome quercetin, a lecithin-bound delivery form (branded as Quercefit) engineered to absorb better. It is not an essential nutrient — there is no RDA and no government-set upper limit. Two areas run through the trials and reviews we have read. The larger is blood pressure: three meta-analyses pooling randomized trials of plain quercetin reported small changes in systolic and diastolic readings, concentrated at doses of 500 mg/day and up. These are small research findings and blood pressure is a question for your clinician. The second, thinner area is seasonal allergy symptoms: one randomized trial of a branded phytosome (Yamada 2022, n=66 — a single small, industry-associated trial) compared self-reported symptom scores with placebo over four weeks. We draw no conclusion from it.
The absorption problem — the #1 buyer-relevant fact
Plain quercetin is poorly absorbed. A randomized crossover pharmacokinetic trial (Riva 2019, n=12) measured plasma quercetin after 500 mg of plain quercetin versus 250 mg or 500 mg of Quercetin Phytosome, and found the phytosome form reached plasma levels up to 20 times higher at the same labeled milligram amount. That single fact explains why the blood-pressure trials (which mostly used plain quercetin at 500–1000 mg/day) and the allergy trial (which used 200 mg/day of phytosome) used such different-looking dose numbers — they are not the same dose delivered in a smaller pill, they are two different absorption curves. Every page in this cluster that states a dose specifies which form it means; see the dosage guide and the buying comparison for why this changes what "cost per mg" even means.
The one-line takeaway Quercetin has been studied for blood pressure and allergy symptoms; results were small, and none of it is a claim that quercetin treats a condition. Plain and phytosome mg are not interchangeable — Riva 2019 found up to a 20x absorption gap at the same label mg. See best quercetin for products ranked by form.
Safety, briefly
Adverse effects from supplemental quercetin are rarely reported and generally mild at doses tested up to about 1000 mg/day (Andres 2018). Two things worth knowing: a theoretical (animal-data-based) nephrotoxicity concern in people with pre-existing kidney impairment, and a real drug-interaction mechanism — quercetin can alter the metabolism of certain co-administered drugs, so check with a pharmacist if you take quinolone antibiotics, anticoagulants/blood thinners, or CYP450-metabolized medications. No long-term (12-week+) high-dose human safety data exists. Full detail on the dosage guide.
On this page
Quercetin Side Effects: Kidney Caution and Interactions
Looking for a tested product? See our best quercetin ranked separately by form and cost per mg, since plain and phytosome are not the same dose →
Short-term oral tolerability: what the trials that tested it directly found
The most direct evidence on tolerability comes from trials designed to test it. A dose-escalation safety study (Han 2020) tested oral quercetin at 500, 1,000, and then 2,000mg/day over one week and reported it was tolerated, with no study-drug-related severe adverse events based on lung function, complete blood counts, or a comprehensive metabolic panel. A 28-day trial in healthy adults (Conquer 1998) at 1,000mg/day reported no adverse changes on the cardiovascular and metabolic markers it measured. A dedicated safety review of the published human intervention literature (Andres 2018) summarizes the pattern across studies: adverse effects following supplemental quercetin intake have been rarely reported, and any such effects were mild in nature.
None of this is long-term data. Andres 2018 is explicit that adequate safety data for high supplemental doses (1,000mg/day and up) used for longer than about 12 weeks doesn't exist yet.
The kidney caution — and why intravenous quercetin is not the same story as an oral capsule
The nephrotoxicity reports that circulate about quercetin come from a Phase I trial of intravenous quercetin, not oral supplementation. A Phase I clinical trial of intravenous quercetin (Ferry 1996) used IV bolus doses of 945–1,700 mg/m² and found dose-limiting nephrotoxicity: at 1,400 mg/m², 2 of 10 evaluable patients had renal toxicity (one grade 2, one grade 4); at 945 mg/m², 3 of 14 patients had clinically significant renal toxicity. At the recommended weekly dose, patients showed an average 19% fall in glomerular filtration rate in the 24 hours after each infusion. Those are IV doses that bypass digestion and first-pass metabolism entirely — they put far more quercetin directly into the bloodstream than any oral capsule can, so this trial does not show what an oral supplement does.
What does carry over to oral use is a narrower, theoretical caution: based on animal studies, quercetin has the potential to worsen nephrotoxic effects specifically in an already-damaged kidney (Andres 2018). People with pre-existing kidney disease should talk to a doctor before supplementing. No human oral trial — including the 1,000–2,000mg/day trials above — has reported kidney injury.
Quinolone antibiotics: a possible interaction
Quinolone antibiotics — ciprofloxacin, levofloxacin, and related drugs — work by binding to bacterial DNA gyrase and blocking it. A structural pharmacology study (Hilliard 1995) found that flavone compounds, quercetin among them, can bind at or near that same active site on DNA gyrase. That overlap means quercetin taken alongside a quinolone antibiotic could compete with the drug for its own bacterial target — a mechanism that, if it plays out in the body the way it does in binding studies, would blunt the antibiotic rather than add anything useful to it. This is a mechanistic/binding-site finding rather than a clinical trial measuring infection outcomes. If you're prescribed a quinolone antibiotic, check with your doctor or pharmacist before taking quercetin.
CYP3A4 and cyclosporine-class drugs — unpredictable direction
Quercetin measurably inhibits CYP3A4 — the liver and intestinal enzyme responsible for clearing cyclosporine, many statins, and a long list of other narrow-therapeutic-window drugs. In human liver and intestinal microsomes, quercetin inhibited CYP3A4-mediated metabolism of a model drug substrate (Fasinu 2013), the kind of finding usually cited as reason to expect quercetin will raise blood levels of CYP3A4-cleared drugs.
But the one study that actually measured quercetin's effect on a real CYP3A4 substrate drug in a living system found the opposite direction. Repeated quercetin dosing in rats lowered cyclosporine's blood levels — peak concentration fell 46–50% and total exposure (AUC) fell 16–34% — through a combined effect on intestinal and hepatic drug-metabolizing enzymes and transporters, not simple enzyme inhibition (Liu 2016). No human pharmacokinetic trial has tested quercetin against cyclosporine or a comparable CYP3A4-cleared drug directly, so which direction this goes in a person — higher drug levels, lower drug levels, or both depending on timing and dose — is not something the current evidence can predict. That unpredictability is itself the reason for caution: if you take cyclosporine, a statin, or any other CYP3A4-metabolized medication with a narrow safety margin, don't assume quercetin is neutral, and check with a doctor or pharmacist before combining them.
Enhanced-absorption forms change the exposure a tolerated-dose number is based on
Every dose figure above — the 1,000–2,000mg/day tolerated in Han 2020 and Conquer 1998, the "rarely reported, mild" pattern in Andres 2018 — was established using plain (unformulated) quercetin dihydrate. Phytosome quercetin (lecithin-bound, branded Quercefit) is a different exposure at the same label number: a randomized crossover pharmacokinetic trial (Riva 2019) found it reaches plasma concentrations up to 20 times higher than plain quercetin at an identical labeled mg dose. Enzymatically modified isoquercitrin (EMIQ), engineered with a different chemistry, similarly reaches substantially higher blood concentrations than unmodified quercetin (Owczarek-Januszkiewicz 2022).
Neither enhanced-absorption form has its own dedicated long-term safety trial at the doses now sold commercially — the tolerability data above is plain-quercetin data. A "1,000mg is well tolerated" conclusion, applied uncritically to a phytosome or EMIQ product labeled the same 1,000mg, is comparing a known short-term safety record to an unmeasured, higher actual exposure. See the dosage guide for how the trial doses map to each form.
Quercetin side effects at a glance
| Concern | What the evidence shows | Route / form it applies to | When it matters |
|---|---|---|---|
| General short-term tolerability | Reported as tolerated up to 1,000–2,000mg/day in trials of 1–4 weeks; no severe drug-related effects reported | Oral, plain quercetin | What short trials in adults reported |
| Kidney injury (nephrotoxicity) | Dose-limiting in a Phase I trial of IV bolus doses (945–1,700mg/m²); a theoretical caution only in a pre-damaged kidney with oral use | Intravenous (Phase I trial doses) ≠ oral supplement | Pre-existing kidney disease (oral); no kidney injury was reported in the oral trials reviewed |
| Quinolone antibiotic interaction | Quercetin can bind the same DNA-gyrase active site quinolones target — may blunt the antibiotic | Oral, any form, taken with ciprofloxacin/levofloxacin/etc. | Ask your doctor or pharmacist if prescribed a quinolone antibiotic |
| CYP3A4 / cyclosporine-class interaction | Inhibits CYP3A4 in vitro; the one in vivo (rat) cyclosporine study found decreased, not increased, drug exposure — direction unpredictable in humans | Oral, any form | Ask your doctor or pharmacist if you take cyclosporine, statins, or other CYP3A4-metabolized drugs |
| Higher exposure per label mg | Phytosome reaches up to 20× higher plasma levels than plain at the same mg; EMIQ similarly enhanced | Phytosome (Quercefit) and EMIQ specifically | Anyone assuming a plain-quercetin tolerated dose transfers directly to an enhanced-absorption label |
| Long-term high-dose safety | No human trial has studied doses ≥1,000mg/day for longer than about 12 weeks | Oral, any form | Anyone planning ongoing daily use above 1,000mg/day |
Common questions
What are the most common quercetin side effects?
Short-term oral quercetin is well tolerated in the human trials that have specifically tested it. A dose-escalation safety trial (Han 2020) reported doses up to 2,000mg/day were tolerated over one week, with no drug-related severe adverse events on blood work or lung function. A 28-day trial at 1,000mg/day in healthy adults (Conquer 1998) reported no adverse effects distinguishable from baseline. A broader safety review of published human intervention studies (Andres 2018) describes adverse effects following supplemental quercetin as rarely reported and mild when they occur. The important gap: no human trial has tested high-dose oral quercetin (1,000mg/day or more) for longer than about 12 weeks, so long-term safety at high doses is unknown.
I've heard quercetin can hurt your kidneys — is that true?
It depends entirely on the route and the dose, and the two are often mixed up. The kidney injury reports come from intravenous quercetin — a Phase I trial (Ferry 1996) using IV bolus doses of 945-1,700mg/m² found dose-limiting nephrotoxicity, including a measurable fall in glomerular filtration rate after dosing and grade 2-4 renal toxicity in some patients at the higher doses tested. That is a different substance exposure entirely from an oral supplement capsule: those IV doses bypass absorption and first-pass metabolism completely, delivering blood concentrations an oral dose cannot reach. Separately, animal studies have identified a theoretical concern that oral quercetin could worsen nephrotoxic effects specifically in an already-damaged kidney (Andres 2018) — a reason for caution if you have pre-existing kidney disease, not evidence that oral quercetin harms healthy kidneys. No oral human trial has reported kidney injury at the doses sold as supplements.
Does quercetin interact with antibiotics?
Yes — with quinolone antibiotics specifically (ciprofloxacin, levofloxacin, and related drugs), and the mechanism is structural, not metabolic. Quinolone antibiotics work by binding to bacterial DNA gyrase. Quercetin, structurally, is also able to bind at or near that same active site (Hilliard 1995) — so taking the two together may mean quercetin competes with the antibiotic for its bacterial target, a mechanism that could blunt the antibiotic's effectiveness rather than add to its action. This is a binding-site/mechanistic finding, not a clinical outcomes trial. If you take a quinolone antibiotic, check with your doctor or pharmacist before taking quercetin.
Does quercetin affect how other drugs are metabolized (CYP3A4)?
Yes, and the honest answer is that quercetin is a real CYP3A4 modulator but the net effect on a specific drug isn't reliably predictable from that fact alone. In human liver and intestinal microsomes, quercetin measurably inhibits CYP3A4-mediated metabolism of a model drug (Fasinu 2013) — the enzyme that clears cyclosporine, many statins, and other narrow-therapeutic-window medications. But the one whole-animal pharmacokinetic study using an actual CYP3A4 substrate drug, cyclosporine, found the opposite direction of effect in practice: repeated quercetin dosing in rats lowered, not raised, cyclosporine's blood levels (by roughly 16-34% AUC), through a combined effect on metabolizing enzymes and drug transporters (Liu 2016). No human pharmacokinetic trial has tested quercetin against cyclosporine or a similar CYP3A4-cleared drug directly. The practical takeaway is caution, not a predicted direction: if you take cyclosporine, a statin, or any other CYP3A4-metabolized medication with a narrow safety margin, talk to a doctor or pharmacist before adding quercetin rather than assuming it will simply raise or lower your drug levels.
Does the tolerated dose for plain quercetin apply to phytosome or EMIQ formulas too?
No, and this is the detail most side-effect discussions skip. The oral safety data described above — doses up to 1,000-2,000mg/day tolerated over one to twelve weeks — was measured using plain (unformulated) quercetin dihydrate. Enhanced-absorption formulations reach meaningfully higher blood levels at the same labeled milligram amount: a randomized crossover trial (Riva 2019) found phytosome quercetin (Quercefit) reached plasma concentrations up to 20 times higher than plain quercetin at an identical mg dose. Enzymatically modified isoquercitrin (EMIQ), a separate high-absorption form, works through different chemistry to the same end (Owczarek-Januszkiewicz 2022) but similarly increases how much of the labeled dose actually reaches your bloodstream. Neither form has its own dedicated long-term human safety trial at the doses now sold commercially. A "1,000mg is tolerated" conclusion drawn from plain-quercetin tolerability data does not automatically transfer to a phytosome or EMIQ label claiming the same milligram number — the actual systemic exposure is higher.
Frequently asked questions
What have quercetin blood pressure studies found?
Three meta-analyses pooled trials of plain quercetin and reported small changes in blood pressure readings (2-4.5 mmHg), with results at 500 mg/day and up (Serban 2016's dose-stratified data). These are small research findings, not a claim that quercetin manages any condition. Ask your clinician about blood pressure or medicines.
What has been studied for allergies?
One small randomized trial of a branded phytosome (Yamada 2022, n=66, industry-associated) looked at self-reported symptom scores. The trial base is small, and this page draws no conclusion about allergies.
Is plain quercetin the same as phytosome quercetin?
No. Riva 2019 found phytosome reaches up to 20x higher plasma levels than plain at the same mg. A 250mg phytosome capsule and a 250mg plain capsule are different doses.
Related guides
Sources
- Serban C, et al. "Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials." J Am Heart Assoc. 2016. PMID: 27405810
- Huang H, et al. "Effects of quercetin supplementation on cardiovascular risk factors: a systematic review and meta-analysis." Nutr Rev. 2020. PMID: 31940027
- Popiolek-Kalisz J, Fornal E. "The Effects of Quercetin Supplementation on Blood Pressure." Curr Probl Cardiol. 2022. PMID: 35948195
- Yamada A, et al. "Effect of Quercetin Phytosome on allergic symptoms in patients with pollinosis." Eur Rev Med Pharmacol Sci. 2022. PMID: 35776034
- Riva A, et al. "Improved Oral Absorption of Quercetin from Quercetin Phytosome." Eur J Drug Metab Pharmacokinet. 2019. PMID: 30328058
- Andres S, et al. "Safety aspects of the use of quercetin as a dietary supplement." Mol Nutr Food Res. 2018. PMID: 29127724
- Full product dataset: /quercetin/cost-by-brand.json (CC BY 4.0).
- Hilliard JJ, Krause HM, et al. "A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase." Adv Exp Med Biol. 1995. PMID: 8718602
- Han MK, et al. "Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease." BMJ Open Respir Res. 2020 Feb. PMID: 32071149
- Conquer JA, et al. "Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects." J Nutr. 1998. PMID: 9482769
- Ferry DR, et al. "Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition." Clin Cancer Res. 1996 Apr. PMID: 9816216 (intravenous dosing, cancer trial — not oral supplementation).
- Fasinu PS, et al. "Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability." J Pharm Sci. 2013 Feb. PMID: 23188647
- Liu Y, et al. "Impact of quercetin-induced changes in drug-metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats." Mol Med Rep. 2016 Oct. PMID: 27510982 (rat study).